Semaglutide reduces risk for major adverse cardiovascular events in patients with obesity and heart failure
Semaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points compared with placebo in patients with overweight or obesity and heart failure, according to a study published ...
Aug 28, 2024
0
0